"Let us continue to build the resilient vaccine ecosystem. Our world urgently needs one that stands ready to protect every life everywhere," Akasya said during the inaugural session of the 26th Developing Countries Vaccine Manufacturers Network (DCVMN) Annual General Meeting (AGM), here on Wednesday.
With the theme "Advancing Innovation and Building a Resilient Vaccine Ecosystem for a Safer World," Bio Farma, as a co-host and founding member of DCVMN, encouraged all network members to not only expand vaccine manufacturing capacity, but also ensure that innovation, quality, and equitable access go hand in hand.
The various efforts that have been undertaken over the past few years, he said, demonstrate that the strength of global health partnerships lies in the ability of relevant stakeholders to collaborate across borders, share expertise, and empower each other to meet the world's vaccine needs.
Through the 26th AGM DCVMN, Akasya also emphasized the importance of innovation in vaccine development and efforts to address funding issues, as well as the need for stronger networks so that developing countries are not dependent on other countries.
As one of the global vaccine manufacturers, Bio Farma also reiterated its commitment to continuously improve its product capacity to protect the world through vaccines.
Bio Farma is currently the main supplier of polio vaccine. "And for the next, we still want some improvement for our capacity to enhance and to protect the world with various new products which are needed to strengthen public health,” he said.
Meanwhile, Board Chair of DCVMN Adriansjah Azhari noted that the 26th AGM of the DCVMN is not only a reflection of their shared commitment to equitable access to vaccines, but also a celebration of the remarkable progress made together in strengthening global health security.
"DCVMN members have demonstrated resilience, collaboration and leadership in the face of evolving public health challenges. DCVMN stands as a testament to what developing countries have achieved when we work together," he said during the meeting.
Related news: Bio Farma co-hosts 26th DCVMN AGM to strengthen vaccine resilience
Over the past years, the network has continued to grow in impact and influence, from expanding manufacturing capacities to advancing new vaccine technologies.
"Their collective strength lies in their shared vision to make quality vaccines available, affordable and accessible to all," he added.
Hence, Azhari hopes that the 26th AGM could bring all parties together to explore new opportunities to strengthen vaccine security and manufacturing capacity across regions.
"Our discussions will help shape the future of partnership and chart our next steps toward a more resilient and equitable vaccine ecosystem through the advancement of innovations," he remarked.
Established in 2000, DCVMN is a global network comprising 46 vaccine manufacturers from 17 developing countries across Asia, Africa, Europe, and Latin America, including Argentina, Bangladesh, Brazil, China, Ghana, India, Indonesia, Saudi Arabia, Senegal, Serbia, South Africa, South Korea, Thailand, and Vietnam.
This network aims to strengthen the capacity of vaccine manufacturers in developing countries through advocacy, fostering collaborations, increasing wallet share and professional training on technology advancement, research and development, and knowledge transfer.
Related news: Bio Farma strengthens global vaccine development through DCVMN
Reporter: Katriana
Editor: Yuni Arisandy Sinaga
Copyright © ANTARA 2025
